RT info:eu-repo/semantics/article
T1 Hydrosoluble fiber (Plantago ovata husk) and levodopa I: Experimental study of the pharmacokinetic interaction
A1 García, Juan J.
A1 Fernández, Nélida
A1 Carriedo, Demetrio
A1 Diez Liébana, María José
A1 Sahagún , Ana M.
A1 González, Aranzazu
A1 Calle Pardo, Ángela Pilar
A1 Sierra Vega, Matilde
A2 Farmacologia
K1 Ecología. Medio ambiente
K1 Farmacología
K1 Zoología
K1 Levodopa
K1 Plantago ovat husk
K1 Interaction
K1 Pharmacokinetics
K1 Rabbits
K1 Fiber
AB Fiber therapy could be used in patients with Parkinson disease to reduce the symptoms of gastrointestinal disorders; however, it couldinteract with levodopa reducing its effectiveness. In this experimental study we have investigated whether the presence of Plantago ovatahusk (water-soluble fiber) modifies in rabbits the bioavailability and other pharmacokinetic parameters of levodopa (20 mg/kg) whenadministered by the oral route at the same time. We have also studied whether pharmacokinetic modifications are fiber–dose dependent (100and 400 mg/kg). The extent of levodopa absorbed when administering 100 mg/kg of fiber (AUC=43.4 Ag min ml 1) is approximately thesame as when levodopa is administered alone (AUC=47.1 Ag min ml 1); however, Cmax is lower (1.04 versus 1.43 Ag ml 1). Resultsobtained indicate that fiber at the higher dose increases the extent of levodopa absorbed (AUC=62.2 Ag min ml 1), being the value of Cmaxsimilar (1.46 Ag ml 1). The value of tmax increases from 10 min when levodopa is administered alone to 20 min when the animals receivefiber. On the other hand, since certain time on, levodopa concentrations are always higher in the groups that receive fiber: 60 min with 100mg/kg fiber and 20 min with 400 mg/kg fiber. Fiber also increases the mean residence time (MRT). P. ovata husk administration withlevodopa could be beneficial, not only in patients with constipation, due to: lower adverse reactions (lower values of Cmax) and longer andmore stable effects (higher final concentrations and more time in the body).
PB Elsevier
YR 2015
FD 2015-07-31
LK http://hdl.handle.net/10612/4478
UL http://hdl.handle.net/10612/4478
NO European neuropsychopharmacology, 2005, n. 15
NO P. 497.503
DS BULERIA. Repositorio Institucional de la Universidad de León
RD 05-may-2024